Compare AbbVie Inc (ABBV) vs NIO Inc. (NIO) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

NIO trades at $4.74, up 3.04% today but remains under pressure with a bearish technical signal. The company shows strong revenue growth to $87.49 billion in 2025, but profitability remains elusive with a net loss of $15.57 billion. Analyst sentiment is mixed with a 54% buy rating, while recent news highlights delivery growth amid a challenging EV market.

NIO's outlook hinges on achieving profitability amid fierce competition. The stock offers potential for recovery if cost controls improve and deliveries accelerate, but risks include persistent losses, high debt, and macroeconomic pressures in China. Investor patience is required given the long path to sustained earnings.